Phentermine vs GLP-1: Weight Loss, Safety, Cost (2026)

The short answer

Phentermine is a cheap generic stimulant pill that curbs appetite. GLP-1 drugs like Wegovy and Zepbound act on gut hormones and lead to about two to three times more weight loss in their trials. The FDA label limits phentermine to short-term use, but the new NIH-funded LEAP trial, shown at ObesityWeek 2026, found people on phentermine for two years still had about 6% weight loss, with no average rise in blood pressure. On either drug, Sharpy helps you keep the loss coming from fat, not muscle, with one protein target and one 20-minute workout a day.

Phentermine vs GLP-1: which one works better for weight loss? GLP-1 drugs win on results. Wegovy (semaglutide) led to about 15% weight loss in its main trial and Zepbound (tirzepatide) up to about 21%. Phentermine, a cheap generic appetite pill, led to about 8% at one year and 6% at two years in the new LEAP trial. Phentermine's big edge is price. Its big limit is that the FDA label calls for short-term use only.

That LEAP trial is why this question is back in the news. Researchers at Wake Forest University School of Medicine shared its first two-year results at ObesityWeek 2026 in mid-November. Here is what it found and how phentermine stacks up against the GLP-1s, side by side.

What is the difference between phentermine and a GLP-1?

They work in very different ways.

Phentermine is a stimulant. It is a sympathomimetic amine, a cousin of amphetamine, that turns down hunger through the brain's alert system. It has been sold since 1959. Because it can be misused, it is a Schedule IV controlled substance. Common brands include Adipex-P and Lomaira, and generics are widely sold.

GLP-1 drugs copy a gut hormone. They slow how fast your stomach empties and quiet hunger and "food noise" in the brain. Semaglutide (Wegovy, Ozempic) is a GLP-1. Tirzepatide (Zepbound, Mounjaro) acts on both GLP-1 and GIP. Our guide to GLP-1 vs GIP explains the two hormones.

Phentermine vs semaglutide vs tirzepatide: side-by-side

Phentermine Wegovy (semaglutide) Zepbound (tirzepatide)
Type Stimulant appetite suppressant GLP-1 GLP-1 and GIP
Form Pill or capsule Weekly shot or daily pill Weekly shot
FDA approved use Short-term (a few weeks) add-on to diet and exercise Long-term weight management Long-term weight management
Who it is for (label) BMI 30+, or 27+ with a risk factor BMI 30+, or 27+ with a weight-related condition BMI 30+, or 27+ with a weight-related condition
Average weight loss in trials About 8% at 1 year, 6% at 2 years (LEAP) 14.9% at 68 weeks (STEP 1) Up to 20.9% at 72 weeks (SURMOUNT-1)
Controlled substance Yes, Schedule IV No No
Main side effects Fast heartbeat, higher blood pressure, trouble sleeping, dry mouth, restlessness Nausea, diarrhea, vomiting, constipation Nausea, diarrhea, vomiting, constipation
Self-pay cost Low-cost generic, price varies by pharmacy $349 a month for the pen; pill from $149 $299 to $449 a month for the KwikPen

Trial results come from different studies with different people, so they are not a head-to-head test. Self-pay prices are the makers' own, checked in October 2026; see our weight loss pill cost guide for every dose.

What the new LEAP phentermine trial found

LEAP is funded by the National Institutes of Health and run at Wake Forest. Adults with obesity were randomly given phentermine (24 mg a day) or a placebo pill for two years. Both groups also got lifestyle support.

  • Weight loss: about 8% of starting weight at one year and about 6% at two years on phentermine. Weight loss was greater than placebo the whole way through. Medscape's report from the meeting put the two-year numbers at 6.2% for phentermine and 4.7% for placebo.
  • Blood pressure: on average, it did not go up. Blood pressure was well controlled when people joined.
  • Heart rate: on average, it rose by about 3 to 5 beats per minute.
  • Who was left out: people with heart disease or uncontrolled high blood pressure. So the trial says nothing about long-term use for them.

These are first results from a meeting, not yet a published paper. The researchers framed it around a real problem: patients ask what to do when their insurance stops paying for a GLP-1 or they cannot afford one. Our guide to insurance dropping GLP-1 coverage in 2027 covers that side.

An older study pointed the same way. A 2019 Kaiser Permanente Washington review of health records found that people who kept taking phentermine past three months lost more weight over two years than people who stopped sooner. That study was not randomized, which is why LEAP matters.

Phentermine vs Zepbound for weight loss

Zepbound led to the most weight loss of any approved obesity drug in its trials. In SURMOUNT-1, people on the top dose lost an average of 20.9% of their body weight at 72 weeks, compared with 3.1% on placebo. That is about three times what phentermine did in LEAP.

Zepbound also has FDA approvals beyond weight, such as moderate to severe obstructive sleep apnea in adults with obesity. Phentermine has no approvals beyond short-term weight loss. The trade-off is price and access: Zepbound costs hundreds of dollars a month without coverage.

Phentermine vs semaglutide (Wegovy and Ozempic)

In STEP 1, people on Wegovy 2.4 mg lost an average of 14.9% at 68 weeks, compared with 2.4% on placebo. Wegovy also has an FDA approval to lower the risk of heart attack, stroke and heart death in adults with heart disease and excess weight. Phentermine's label lists heart disease as a reason not to take it at all.

Ozempic is the same medicine as Wegovy, but it is approved for type 2 diabetes, not weight loss. If you are comparing pills, our guide on GLP-1 pill vs shot covers the Wegovy pill and Foundayo.

Phentermine vs Qsymia

Qsymia pairs phentermine with extended-release topiramate, a seizure and migraine medicine. Unlike plain phentermine, it is FDA approved for long-term weight management in adults and in teens 12 and older. In its two-year SEQUEL study, people on the top dose kept off an average of 10.5% of their weight at 108 weeks, compared with 1.8% on placebo. Topiramate can harm an unborn baby, so the label requires pregnancy tests and birth control for women who can get pregnant.

Who should not take phentermine?

The FDA label lists these as reasons not to take it:

  • A history of heart disease, including uncontrolled high blood pressure
  • Taking an MAO inhibitor now or in the last 14 days
  • An overactive thyroid
  • Glaucoma
  • Agitated states, or a history of drug abuse
  • Pregnancy or breastfeeding

It is not recommended for anyone 16 or younger. Take it early in the day, because it can keep you awake. If you are pregnant, under 18 or have a history of an eating disorder, talk to a doctor before any weight loss drug.

Can phentermine and a GLP-1 be taken together?

There is no FDA-approved product that combines them, and neither label covers using both. Some obesity doctors do prescribe them together, with heart rate and blood pressure checks. That is a choice for you and your prescriber. Do not add one to the other, or switch from one to the other, on your own.

Phentermine and exercise: protecting muscle on any weight loss drug

Whichever drug you take, part of the weight you lose can be muscle. Strength training and enough protein are the two habits that protect it best. Phentermine can also raise your heart rate, so start workouts gently and tell your prescriber if you feel your heart racing or pounding.

Sharpy gives you one protein target, one 20-minute strength workout and one Shape Score each day, so you can see whether your loss is coming from fat. Our beginner strength program for GLP-1 users works the same way on phentermine.

The bottom line

GLP-1 drugs lead to much more weight loss than phentermine, and they are approved for long-term use. Phentermine is cheap and, based on LEAP, may hold modest results for two years in people without heart disease. If cost is what stands between you and treatment, ask your prescriber whether phentermine, Qsymia, a self-pay GLP-1 pill or a cash program fits you. And keep your muscle either way: Sharpy makes the protein and strength part simple.

Sources

Questions people ask

Is phentermine better than a GLP-1 for weight loss?

Not on average. In their main trials, semaglutide (Wegovy) led to about 15% weight loss and tirzepatide (Zepbound) up to about 21%. Phentermine alone led to about 8% at one year and 6% at two years in the LEAP trial. Phentermine costs far less, so for some people it is the option they can actually get. Your prescriber can help you weigh that.

Can phentermine and Ozempic be taken together?

No product combines them, and neither label covers using them together. Some doctors do prescribe the two at once, but that is a medical decision with heart rate and blood pressure checks. Do not add one to the other on your own.

Can phentermine and Wegovy be taken together?

The same answer as for Ozempic, since both contain semaglutide. There is no FDA-approved combination, and the decision belongs to your prescriber.

Is phentermine safe long term?

The FDA label says short-term use, a few weeks. The NIH-funded LEAP trial now has two years of randomized data: average blood pressure did not rise and heart rate rose by about 3 to 5 beats per minute. People with heart disease or uncontrolled high blood pressure were excluded, so the results do not apply to them. The full results are not yet published.

Phentermine vs Qsymia: what is the difference?

Qsymia combines phentermine with extended-release topiramate. It is FDA approved for long-term weight management, while plain phentermine is approved for short-term use. Qsymia led to more weight loss in its trials than phentermine alone.

What is better than phentermine for weight loss?

In trials, tirzepatide (Zepbound) and semaglutide (Wegovy shot or pill) led to the most weight loss of any approved drugs. The Foundayo and Wegovy pills are newer options. Which is better for you depends on your health, your coverage and your budget.

Read next